osteoporosis/phosphatase

FIELD OF THE INVENTION This invention relates to a method of inhibiting Protein Tyrosine Phosphatase 1B (PTP1B) and/or T-cell Protein Tyrosine Phosphatase (TC-PTP) and/or Protein Tyrosine Phosphatases (PTPases) having an aspartic acid (Asp) in position 48 (PTP1B numbering, Chernoff et al., Proc.

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

FIELD OF THE INVENTION The present invention relates to, inter alia, novel trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds, their physiologically acceptable salts and prodrugs, which modulate the activity of protein phosphatases and uses thereof. The invention also relates to the

FIELD OF THE INVENTION The present invention in the field of biochemistry and cell and molecular biology relates to the discovery of a novel transmembrane receptor-type protein tyrosine phosphatase termed osteotesticular protein tyrosine phosphatase (OST-PTP). The cloning and sequencing of the RNA

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

TECHNICAL FIELD OF THE INVENTION The invention relates to the regulation of human protein phosphatase IIC-like enzyme activity for therapeutic effects. BACKGROUND OF THE INVENTION The protein phosphorylation/dephosphorylation cycle is one of the major regulatory mechanisms employed by eukaryotic

FIELD OF THE INVENTION The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications induced by infections with Gram-negative bacteria, including sepsis. In particular the invention is directed at systemically applicable compositions. The compositions

FIELD OF THE INVENTION This invention relates to the use of mutant phosphatase and protease enzymes in a competitive binding assay. Specific examples are the enzymes, tyrosine phosphatase and cysteine protease, e.g. Cathepsin K, and the assay specifically described is a scintillation proximity assay

This application is the National Stage of Application No. PCT/EP2006/046543, filed on Dec. 6, 2006, which claims benefit under 35 U.S.C. .sctn.119(a-d) of U.S. Provisional Application No. 60/748,491, filed Dec. 8, 2005, the contents of which are incorporated herein by reference in their

FIELD OF THE INVENTION The present invention is directed to a method of up-regulating the expression of those genes in stem cells that can be induced to regulate bone and cartilage growth and repair by application of an appropriate electric or electromagnetic field. The genes include bone

The invention relates to the use of activated recombinant TRAP (tartrate-resistant and purple acid phosphatases) for screening for specific inhibitor of TRAP activity useful in the treatment of diseases or degenerative conditions resulting in increased bone resorption, such as tissue damages, bone

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a biosensor and method for bone mineral density measurement, which can monitor changes in bone mineral density (BMD) by detecting the content of tartrate-resistant acid phosphatase (TRAP) in blood. 2. Description

FIELD OF THE INVENTION The present invention relates to a method of measuring the bone resorption rate, and particularly to an immunoassay therefor. The invention further relates to a method of diagnosing a disorder associated with a change in the bone resorption rate such as osteoporosis, and to a